Workflow
SpringWorks Therapeutics(SWTX)
icon
Search documents
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
Newsfilter· 2024-08-07 10:30
– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), ...
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire News Room· 2024-08-07 10:30
– Achieved $40.2 million in OGSIVEO® (nirogacestat) net product revenue in the second quarter – – Completed submission of NDA to the FDA for mirdametinib for the treatment of children and adults with NF1-PN – – Presented Phase 2b ReNeu trial results and additional analyses from Phase 3 DeFi trial at the 2024 ASCO Annual Meeting – – Initiated Phase 1a trial of SW-682 in patients with Hippo mutant solid tumors – STAMFORD, Conn., Aug. 07, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), ...
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
Newsfilter· 2024-07-29 10:30
Core Insights - SpringWorks Therapeutics, Inc. has appointed Martin Mackay, Ph.D. to its Board of Directors, bringing over 30 years of experience in pharmaceutical and biotech R&D [1][2] - Dr. Mackay's expertise in rare diseases and leadership roles at major companies like Pfizer, AstraZeneca, and Alexion will be valuable for SpringWorks as it expands its pipeline [2] - SpringWorks is focused on developing life-changing medicines for severe rare diseases and cancer, with its first FDA-approved therapy being OGSIVEO® (nirogacestat) for desmoid tumors [3] Company Overview - SpringWorks Therapeutics is a commercial-stage biopharmaceutical company that applies a precision medicine approach [3] - The company has a diversified pipeline targeting solid tumors and hematological cancers, with programs at various stages from preclinical to advanced clinical trials [3] - SpringWorks has established collaborations with industry and academic innovators to enhance its portfolio and create more solutions for patients [3] Leadership and Experience - Dr. Mackay is a co-founder and Executive Chairman of Rallybio, a clinical-stage biotechnology company focused on severe rare diseases [2] - His previous roles include Executive Vice President at Alexion and President of R&D at AstraZeneca, where he led global R&D functions [2] - Dr. Mackay has held various positions at Pfizer, including Senior Vice President of Worldwide Development, contributing to a wide range of investigational medicines [2] Educational Background - Dr. Mackay holds a First-Class Honours Degree in microbiology from Heriot-Watt University and a Ph.D. in molecular genetics from the University of Edinburgh [2]
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
GlobeNewswire News Room· 2024-07-29 10:30
STAMFORD, Conn., July 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the appointment of Martin Mackay, Ph.D. to the Company's Board of Directors. Dr. Mackay is a highly accomplished research and development (R&D) executive with more than 30 years of pharmaceutical and biotech R&D experience, including leadership roles at Pfizer, AstraZeneca and Alexion. "Martin is a proven in ...
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
Newsfilter· 2024-07-23 11:00
STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by ph ...
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
GlobeNewswire News Room· 2024-07-23 11:00
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube. Samantha Hilson Sandler Senior Director, Investor Relations Phone: 203-461-5501 Email: samantha.sandler@springworkstx.com STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a. ...
SpringWorks (SWTX) Rises More Than 40% in a Year: Here's Why
ZACKS· 2024-07-12 16:32
Earlier this month, the company completed the new drug application (NDA) submission for its investigational MEK inhibitor, mirdametinib, which is being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients. SWTX plans to file a marketing application with the European Medicines Agency seeking approval for mirdametinib for the treatment of children and adults with NF1-PN later in the second half of 2024. Following the FDA nod, not ...
SpringWorks (SWTX) Completes NDA Submission for Mirdametinib
ZACKS· 2024-07-02 17:16
The NDA filing was based on data from the pivotal phase IIb ReNeu study, which evaluated mirdametinib in patients aged two years and above with NF1-associated PN causing significant morbidity. SpringWorks Therapeutics, Inc. (SWTX) announced that it has completed the submission of a new drug application ("NDA") for its investigational MEK inhibitor, mirdametinib, being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients. The pr ...
Kuehn Law Encourages Investors of SpringWorks, Therapeutics Inc. to Contact Law Firm
Prnewswire· 2024-07-02 16:49
NEW YORK, July 2, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. Why Your Participation Matters: For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Contacts: Kuehn Law, P ...
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
Newsfilter· 2024-07-01 10:30
"We are pleased to be one step closer towards our goal of bringing mirdametinib to patients with NF1-PN in the U.S. and believe that our ReNeu data support the potential for mirdametinib to be a differentiated and best-inclass therapy for both children and adults living with this devastating disease," said Saqib Islam, Chief Executive Officer of SpringWorks. "We look forward to working closely with the FDA throughout the review process and also plan to file for regulatory approval in the European Union late ...